$AVNR Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in AVANIR PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in AVANIR PHARMACEUTICALS, INC.. Get notifications about new insider transactions in AVANIR PHARMACEUTICALS, INC. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 10 2008 | AVNR | AVANIR PHARMACEUTI ... | Moorin Jay | 10% Owner | Buy | P | 0.92 | 146,400 | 134,688 | 8,775,707 | 8.6 M to 8.8 M (+1.70 %) |
| Sep 10 2008 | AVNR | AVANIR PHARMACEUTI ... | Moorin Jay | 10% Owner | Buy | P | 0.95 | 125,000 | 118,750 | 8,629,307 | 8.5 M to 8.6 M (+1.47 %) |
| Sep 04 2008 | AVNR | AVANIR PHARMACEUTI ... | Moorin Jay | 10% Owner | Buy | P | 0.95 | 52,113 | 49,507 | 8,504,307 | 8.5 M to 8.5 M (+0.62 %) |
| Sep 04 2008 | AVNR | AVANIR PHARMACEUTI ... | Moorin Jay | 10% Owner | Buy | P | 0.93 | 6,864 | 6,384 | 8,452,194 | 8.4 M to 8.5 M (+0.08 %) |
| Sep 04 2008 | AVNR | AVANIR PHARMACEUTI ... | Moorin Jay | 10% Owner | Buy | P | 0.93 | 323,550 | 300,902 | 8,445,330 | 8.1 M to 8.4 M (+3.98 %) |
| Aug 29 2008 | AVNR | AVANIR PHARMACEUTI ... | Moorin Jay | 10% Owner | Buy | P | 0.95 | 89,447 | 84,975 | 8,121,780 | 8 M to 8.1 M (+1.11 %) |
| Aug 08 2008 | AVNR | AVANIR PHARMACEUTI ... | Moorin Jay | 10% Owner | Buy | P | 0.98 | 91,380 | 89,552 | 7,912,250 | 7.8 M to 7.9 M (+1.17 %) |
| Aug 08 2008 | AVNR | AVANIR PHARMACEUTI ... | Moorin Jay | 10% Owner | Buy | P | 0.90 | 400 | 360 | 7,820,870 | 7.8 M to 7.8 M (+0.01 %) |
| Aug 18 2008 | AVNR | AVANIR PHARMACEUTI ... | Moorin Jay | 10% Owner | Buy | P | 0.95 | 114,032 | 108,330 | 8,032,333 | 7.9 M to 8 M (+1.44 %) |
| Aug 18 2008 | AVNR | AVANIR PHARMACEUTI ... | Moorin Jay | 10% Owner | Buy | P | 0.90 | 6,051 | 5,446 | 7,918,301 | 7.9 M to 7.9 M (+0.08 %) |
| Jun 16 2008 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Payment of Exercise | F | 1.11 | 1,287 | 1,429 | 578,442 | 579.7 K to 578.4 K (-0.22 %) |
| Jun 16 2008 | AVNR | AVANIR PHARMACEUTI ... | Kaye Randall | Chief Medical Offic ... | Payment of Exercise | F | 1.11 | 1,217 | 1,351 | 416,955 | 418.2 K to 417 K (-0.29 %) |
| Mar 17 2008 | AVNR | AVANIR PHARMACEUTI ... | Kaye Randall | Chief Medical Offic ... | Payment of Exercise | F | 1.10 | 1,440 | 1,584 | 418,172 | 419.6 K to 418.2 K (-0.34 %) |
| Mar 17 2008 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Payment of Exercise | F | 1.10 | 1,539 | 1,693 | 579,729 | 581.3 K to 579.7 K (-0.26 %) |
| Feb 25 2008 | AVNR | AVANIR PHARMACEUTI ... | Podlesak Dennis | Director | Grant | A | 0.00 | 56,911 | 0 | 108,594 | 51.7 K to 108.6 K (+110.12 %) |
| Feb 25 2008 | AVNR | AVANIR PHARMACEUTI ... | AUSTIN STEPHEN G | Director | Grant | A | 0.00 | 56,911 | 0 | 110,094 | 53.2 K to 110.1 K (+107.01 %) |
| Feb 25 2008 | AVNR | AVANIR PHARMACEUTI ... | Whitcup Scott M | Director | Grant | A | 0.00 | 56,911 | 0 | 107,594 | 50.7 K to 107.6 K (+112.29 %) |
| Feb 25 2008 | AVNR | AVANIR PHARMACEUTI ... | Mazzo David J | Director | Grant | A | 0.00 | 56,911 | 0 | 108,594 | 51.7 K to 108.6 K (+110.12 %) |
| Feb 25 2008 | AVNR | AVANIR PHARMACEUTI ... | MATHEWS CHARLES | Director | Grant | A | 0.00 | 56,911 | 0 | 111,969 | 55.1 K to 112 K (+103.37 %) |
| Feb 25 2008 | AVNR | AVANIR PHARMACEUTI ... | WHEELER CRAIG A | Director | Grant | A | 0.00 | 56,911 | 0 | 107,594 | 50.7 K to 107.6 K (+112.29 %) |
| Jan 22 2008 | AVNR | AVANIR PHARMACEUTI ... | Kaye Randall | Chief Medical Offic ... | Option Exercise | M | 0.04 | 12,500 | 500 | 0 | |
| Jan 22 2008 | AVNR | AVANIR PHARMACEUTI ... | Kaye Randall | Chief Medical Offic ... | Payment of Exercise | F | 1.13 | 4,983 | 5,631 | 419,612 | 424.6 K to 419.6 K (-1.17 %) |
| Jan 22 2008 | AVNR | AVANIR PHARMACEUTI ... | Kaye Randall | Chief Medical Offic ... | Buy | M | 0.04 | 12,500 | 500 | 424,595 | 412.1 K to 424.6 K (+3.03 %) |
| Dec 17 2007 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Payment of Exercise | F | 1.66 | 5,148 | 8,546 | 581,268 | 586.4 K to 581.3 K (-0.88 %) |
| Dec 17 2007 | AVNR | AVANIR PHARMACEUTI ... | Kaye Randall | Chief Medical Offic ... | Payment of Exercise | F | 1.66 | 5,148 | 8,546 | 412,095 | 417.2 K to 412.1 K (-1.23 %) |
| Dec 06 2007 | AVNR | AVANIR PHARMACEUTI ... | Kaye Randall | Chief Medical Offic ... | Grant | A | 0.00 | 107,143 | 0 | 417,243 | 310.1 K to 417.2 K (+34.55 %) |
| Sep 12 2007 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Option Exercise | A | 2.41 | 120,781 | 291,082 | 120,781 | |
| May 08 2007 | AVNR | AVANIR PHARMACEUTI ... | PUNTORIERO MICHAEL J | Senior VP, Finance, ... | Payment of Exercise | F | 3.38 | 1,192 | 4,029 | 74,533 | 75.7 K to 74.5 K (-1.57 %) |
| May 08 2007 | AVNR | AVANIR PHARMACEUTI ... | PUNTORIERO MICHAEL J | Senior VP, Finance, ... | Option Exercise | M | 0.00 | 10,000 | 10 | 0 | |
| May 08 2007 | AVNR | AVANIR PHARMACEUTI ... | PUNTORIERO MICHAEL J | Senior VP, Finance, ... | Grant | A | 0.00 | 10,000 | 10 | 75,725 | 65.7 K to 75.7 K (+15.21 %) |
| Mar 22 2007 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Option Exercise | A | 1.29 | 130,960 | 168,938 | 130,960 | |
| Mar 22 2007 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Grant | A | 0.00 | 53,126 | 0 | 586,416 | 533.3 K to 586.4 K (+9.96 %) |
| Mar 22 2007 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | President and CEO | Grant | A | 0.00 | 473,190 | 0 | 533,290 | 60.1 K to 533.3 K (+787.34 %) |
| Mar 22 2007 | AVNR | AVANIR PHARMACEUTI ... | Kaye Randall | SVP, Chief Medical ... | Grant | A | 0.00 | 250,000 | 0 | 309,600 | 59.6 K to 309.6 K (+419.46 %) |
| Mar 22 2007 | AVNR | AVANIR PHARMACEUTI ... | Sturgeon Martin J | VP, Chief Accountin ... | Grant | A | 0.00 | 86,071 | 0 | 96,071 | 10 K to 96.1 K (+860.71 %) |
| Mar 07 2007 | AVNR | AVANIR PHARMACEUTI ... | BRANDT ERIC | President, CEO & Di ... | Payment of Exercise | F | 1.29 | 7,425 | 9,578 | 351,482 | 358.9 K to 351.5 K (-2.07 %) |
| Mar 05 2007 | AVNR | AVANIR PHARMACEUTI ... | Mazzo David J | Director | Grant | A | 0.00 | 11,752 | 0 | 51,683 | 39.9 K to 51.7 K (+29.43 %) |
| Mar 05 2007 | AVNR | AVANIR PHARMACEUTI ... | Mazzo David J | Director | Grant | A | 0.00 | 32,496 | 0 | 39,931 | 7.4 K to 39.9 K (+437.07 %) |
| Mar 05 2007 | AVNR | AVANIR PHARMACEUTI ... | SILVERSTEIN JONATHAN | Director | Grant | A | 0.00 | 11,752 | 0 | 50,683 | 38.9 K to 50.7 K (+30.19 %) |
| Mar 05 2007 | AVNR | AVANIR PHARMACEUTI ... | SILVERSTEIN JONATHAN | Director | Grant | A | 0.00 | 32,496 | 0 | 38,931 | 6.4 K to 38.9 K (+504.99 %) |
| Mar 05 2007 | AVNR | AVANIR PHARMACEUTI ... | Whitcup Scott M | Director | Grant | A | 0.00 | 11,752 | 0 | 50,683 | 38.9 K to 50.7 K (+30.19 %) |
| Mar 05 2007 | AVNR | AVANIR PHARMACEUTI ... | Whitcup Scott M | Director | Grant | A | 0.00 | 32,496 | 0 | 38,931 | 6.4 K to 38.9 K (+504.99 %) |
| Mar 05 2007 | AVNR | AVANIR PHARMACEUTI ... | AUSTIN STEPHEN G | Director | Grant | A | 0.00 | 11,752 | 0 | 53,183 | 41.4 K to 53.2 K (+28.37 %) |
| Mar 05 2007 | AVNR | AVANIR PHARMACEUTI ... | AUSTIN STEPHEN G | Director | Grant | A | 0.00 | 32,496 | 0 | 41,431 | 8.9 K to 41.4 K (+363.69 %) |
| Mar 05 2007 | AVNR | AVANIR PHARMACEUTI ... | WHEELER CRAIG A | Director | Grant | A | 0.00 | 11,752 | 0 | 50,683 | 38.9 K to 50.7 K (+30.19 %) |
| Mar 05 2007 | AVNR | AVANIR PHARMACEUTI ... | WHEELER CRAIG A | Director | Grant | A | 0.00 | 32,496 | 0 | 38,931 | 6.4 K to 38.9 K (+504.99 %) |
| Mar 05 2007 | AVNR | AVANIR PHARMACEUTI ... | Podlesak Dennis | Director | Grant | A | 0.00 | 11,752 | 0 | 51,683 | 39.9 K to 51.7 K (+29.43 %) |
| Mar 05 2007 | AVNR | AVANIR PHARMACEUTI ... | Podlesak Dennis | Director | Grant | A | 0.00 | 32,496 | 0 | 39,931 | 7.4 K to 39.9 K (+437.07 %) |
| Mar 05 2007 | AVNR | AVANIR PHARMACEUTI ... | THOMAS PAUL | Director | Grant | A | 0.00 | 11,752 | 0 | 50,683 | 38.9 K to 50.7 K (+30.19 %) |
| Mar 05 2007 | AVNR | AVANIR PHARMACEUTI ... | THOMAS PAUL | Director | Grant | A | 0.00 | 32,496 | 0 | 38,931 | 6.4 K to 38.9 K (+504.99 %) |
| Mar 05 2007 | AVNR | AVANIR PHARMACEUTI ... | MATHEWS CHARLES | Director | Grant | A | 0.00 | 11,752 | 0 | 53,183 | 41.4 K to 53.2 K (+28.37 %) |
| Mar 05 2007 | AVNR | AVANIR PHARMACEUTI ... | MATHEWS CHARLES | Director | Grant | A | 0.00 | 32,496 | 0 | 41,431 | 8.9 K to 41.4 K (+363.69 %) |
| Dec 15 2006 | AVNR | AVANIR PHARMACEUTI ... | PUNTORIERO MICHAEL J | Senior VP, Finance, ... | Grant | A | 0.00 | 57,600 | 0 | 65,725 | 8.1 K to 65.7 K (+708.92 %) |
| Dec 15 2006 | AVNR | AVANIR PHARMACEUTI ... | HOPEREESE THERESA | VP, Human Resources | Grant | A | 0.00 | 35,600 | 0 | 35,600 | 0 to 35.6 K |
| Dec 14 2006 | AVNR | AVANIR PHARMACEUTI ... | BRANDT ERIC | President, CEO & Di ... | Grant | A | 0.00 | 137,200 | 0 | 358,907 | 221.7 K to 358.9 K (+61.88 %) |
| Dec 14 2006 | AVNR | AVANIR PHARMACEUTI ... | Kaye Randall | VP of Medical Affai ... | Grant | A | 0.00 | 57,600 | 0 | 59,600 | 2 K to 59.6 K (+2,880.00 %) |
| Dec 14 2006 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | Sr. V.P. of Sales & ... | Grant | A | 0.00 | 57,600 | 0 | 60,100 | 2.5 K to 60.1 K (+2,304.00 %) |
| Dec 14 2006 | AVNR | AVANIR PHARMACEUTI ... | SIRCAR JAGADISH C | V.P. of Drug Discov ... | Grant | A | 0.00 | 18,800 | 0 | 31,425 | 12.6 K to 31.4 K (+148.91 %) |
| Dec 14 2006 | AVNR | AVANIR PHARMACEUTI ... | HANSON GREGORY P | VP, CAO & Secretary | Grant | A | 0.00 | 17,400 | 0 | 22,563 | 5.2 K to 22.6 K (+337.01 %) |
| Dec 08 2006 | AVNR | AVANIR PHARMACEUTI ... | BRANDT ERIC | President, CEO & Di ... | Payment of Exercise | F | 2.90 | 9,518 | 27,602 | 221,707 | 231.2 K to 221.7 K (-4.12 %) |
| Sep 22 2006 | AVNR | AVANIR PHARMACEUTI ... | BRANDT ERIC | President, CEO & Di ... | Payment of Exercise | F | 6.73 | 29,775 | 200,386 | 231,225 | 261 K to 231.2 K (-11.41 %) |
| Jun 07 2006 | AVNR | AVANIR PHARMACEUTI ... | SILVERSTEIN JONATHAN | Director | Buy | J | 9.79 | 348 | 3,407 | 6,783 | 6.4 K to 6.8 K (+5.41 %) |
| Jun 07 2006 | AVNR | AVANIR PHARMACEUTI ... | SILVERSTEIN JONATHAN | Director | Sell | S | 9.79 | 629,121 | 6,159,095 | 1,706,137 | 2.3 M to 1.7 M (-26.94 %) |
| Jun 02 2006 | AVNR | AVANIR PHARMACEUTI ... | Podlesak Dennis | Director | Buy | P | 9.91 | 200 | 1,982 | 7,435 | 7.2 K to 7.4 K (+2.76 %) |
| Jun 02 2006 | AVNR | AVANIR PHARMACEUTI ... | Podlesak Dennis | Director | Buy | P | 9.90 | 800 | 7,920 | 7,235 | 6.4 K to 7.2 K (+12.43 %) |
| Jun 02 2006 | AVNR | AVANIR PHARMACEUTI ... | ORBIMED ADVISORS LLC | Director | Sell | S | 9.79 | 629,121 | 6,159,095 | 1,706,137 | 2.3 M to 1.7 M (-26.94 %) |
| Jun 01 2006 | AVNR | AVANIR PHARMACEUTI ... | BERG JAMES E | Vice President, Cli ... | Option Exercise | M | 2.88 | 37,500 | 108,000 | 0 | |
| Jun 01 2006 | AVNR | AVANIR PHARMACEUTI ... | BERG JAMES E | Vice President, Cli ... | Buy | M | 2.88 | 37,500 | 108,000 | 53,000 | 15.5 K to 53 K (+241.94 %) |
| May 26 2006 | AVNR | AVANIR PHARMACEUTI ... | Kaye Randall | VP of Medical Affai ... | Buy | P | 9.90 | 250 | 2,475 | 250 | 0 to 250 |
| May 26 2006 | AVNR | AVANIR PHARMACEUTI ... | Kaye Randall | VP of Medical Affai ... | Buy | P | 9.90 | 200 | 1,980 | 250 | 50 to 250 (+400.00 %) |
| May 26 2006 | AVNR | AVANIR PHARMACEUTI ... | Kaye Randall | VP of Medical Affai ... | Buy | P | 9.89 | 50 | 495 | 50 | 0 to 50 |
| May 26 2006 | AVNR | AVANIR PHARMACEUTI ... | Kaye Randall | VP of Medical Affai ... | Buy | P | 10.14 | 2,000 | 20,280 | 2,000 | 0 to 2 K |
| May 26 2006 | AVNR | AVANIR PHARMACEUTI ... | HANSON GREGORY P | Vice President, CAO | Buy | P | 9.68 | 100 | 968 | 5,163 | 5.1 K to 5.2 K (+1.98 %) |
| May 26 2006 | AVNR | AVANIR PHARMACEUTI ... | HANSON GREGORY P | Vice President, CAO | Buy | P | 9.67 | 100 | 967 | 5,063 | 5 K to 5.1 K (+2.01 %) |
| May 26 2006 | AVNR | AVANIR PHARMACEUTI ... | HANSON GREGORY P | Vice President, CAO | Buy | P | 9.69 | 300 | 2,907 | 4,963 | 4.7 K to 5 K (+6.43 %) |
| May 26 2006 | AVNR | AVANIR PHARMACEUTI ... | HANSON GREGORY P | Vice President, CAO | Buy | P | 9.65 | 600 | 5,790 | 4,663 | 4.1 K to 4.7 K (+14.77 %) |
| May 25 2006 | AVNR | AVANIR PHARMACEUTI ... | PUNTORIERO MICHAEL J | Senior VP, Finance, ... | Buy | P | 9.00 | 2,500 | 22,500 | 8,125 | 5.6 K to 8.1 K (+44.44 %) |
| May 25 2006 | AVNR | AVANIR PHARMACEUTI ... | PUNTORIERO MICHAEL J | Senior VP, Finance, ... | Buy | P | 9.05 | 5,000 | 45,250 | 5,625 | 625 to 5.6 K (+800.00 %) |
| May 25 2006 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | Sr. V.P. of Sales & ... | Buy | P | 9.00 | 1,700 | 15,300 | 2,500 | 800 to 2.5 K (+212.50 %) |
| May 25 2006 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | Sr. V.P. of Sales & ... | Buy | P | 8.98 | 800 | 7,184 | 800 | 0 to 800 |
| May 25 2006 | AVNR | AVANIR PHARMACEUTI ... | EMANUELE ROBERT MARTIN | V P, Business Devel ... | Buy | P | 8.99 | 1,000 | 8,990 | 1,000 | 0 to 1,000 |
| May 25 2006 | AVNR | AVANIR PHARMACEUTI ... | BRANDT ERIC | President, CEO & Di ... | Buy | P | 8.96 | 89 | 797 | 261,000 | 260.9 K to 261 K (+0.03 %) |
| May 25 2006 | AVNR | AVANIR PHARMACEUTI ... | BRANDT ERIC | President, CEO & Di ... | Buy | P | 8.97 | 2,911 | 26,112 | 260,911 | 258 K to 260.9 K (+1.13 %) |
| May 25 2006 | AVNR | AVANIR PHARMACEUTI ... | BRANDT ERIC | President, CEO & Di ... | Buy | P | 8.99 | 1,700 | 15,283 | 258,000 | 256.3 K to 258 K (+0.66 %) |
| May 25 2006 | AVNR | AVANIR PHARMACEUTI ... | BRANDT ERIC | President, CEO & Di ... | Buy | P | 9.00 | 6,300 | 56,700 | 256,300 | 250 K to 256.3 K (+2.52 %) |
| Feb 23 2006 | AVNR | AVANIR PHARMACEUTI ... | ORBIMED ADVISORS LLC | Director | Grant | A | 0.00 | 2,335,258 | 0 | 2,335,258 | 0 to 2.3 M |
| Feb 23 2006 | AVNR | AVANIR PHARMACEUTI ... | ORBIMED ADVISORS LLC | Director | Grant | A | 0.00 | 6,435 | 0 | 6,435 | 0 to 6.4 K |
| Mar 02 2006 | AVNR | AVANIR PHARMACEUTI ... | BERG JAMES E | VP, Clinical & Reg. ... | Option Exercise | M | 10.00 | 750 | 7,500 | 0 | |
| Mar 02 2006 | AVNR | AVANIR PHARMACEUTI ... | BERG JAMES E | VP, Clinical & Reg. ... | Option Exercise | M | 5.88 | 2,500 | 14,688 | 0 | |
| Mar 02 2006 | AVNR | AVANIR PHARMACEUTI ... | BERG JAMES E | VP, Clinical & Reg. ... | Buy | M | 5.88 | 2,500 | 14,688 | 15,500 | 13 K to 15.5 K (+19.23 %) |
| Mar 02 2006 | AVNR | AVANIR PHARMACEUTI ... | BERG JAMES E | VP, Clinical & Reg. ... | Buy | M | 10.00 | 750 | 7,500 | 13,000 | 12.3 K to 13 K (+6.12 %) |
| Feb 22 2006 | AVNR | AVANIR PHARMACEUTI ... | SIRCAR JAGADISH C | VP of Drug Discover ... | Option Exercise | M | 12.00 | 5,000 | 60,000 | 0 | |
| Feb 22 2006 | AVNR | AVANIR PHARMACEUTI ... | SIRCAR JAGADISH C | VP of Drug Discover ... | Sell | S | 16.82 | 3,600 | 60,552 | 12,625 | 16.2 K to 12.6 K (-22.19 %) |
| Feb 22 2006 | AVNR | AVANIR PHARMACEUTI ... | SIRCAR JAGADISH C | VP of Drug Discover ... | Buy | M | 12.00 | 5,000 | 60,000 | 16,225 | 11.2 K to 16.2 K (+44.54 %) |
| Feb 15 2006 | AVNR | AVANIR PHARMACEUTI ... | MATHEWS CHARLES | Director | Grant | A | 0.00 | 6,435 | 0 | 8,935 | 2.5 K to 8.9 K (+257.40 %) |
| Feb 15 2006 | AVNR | AVANIR PHARMACEUTI ... | SILVERSTEIN JONATHAN | Director | Grant | A | 0.00 | 6,435 | 0 | 6,435 | 0 to 6.4 K |
| Feb 15 2006 | AVNR | AVANIR PHARMACEUTI ... | AUSTIN STEPHEN G | Director | Grant | A | 0.00 | 6,435 | 0 | 8,935 | 2.5 K to 8.9 K (+257.40 %) |
| Feb 15 2006 | AVNR | AVANIR PHARMACEUTI ... | Whitcup Scott M | Director | Grant | A | 0.00 | 6,435 | 0 | 6,435 | 0 to 6.4 K |
| Feb 15 2006 | AVNR | AVANIR PHARMACEUTI ... | WHEELER CRAIG A | Director | Grant | A | 0.00 | 6,435 | 0 | 6,435 | 0 to 6.4 K |
| Feb 15 2006 | AVNR | AVANIR PHARMACEUTI ... | Podlesak Dennis | Director | Grant | A | 0.00 | 6,435 | 0 | 6,435 | 0 to 6.4 K |
| Feb 15 2006 | AVNR | AVANIR PHARMACEUTI ... | THOMAS PAUL | Director | Grant | A | 0.00 | 6,435 | 0 | 6,435 | 0 to 6.4 K |
| Feb 15 2006 | AVNR | AVANIR PHARMACEUTI ... | Mazzo David J | Director | Buy | P | 15.59 | 1,000 | 15,590 | 7,435 | 6.4 K to 7.4 K (+15.54 %) |
| Feb 15 2006 | AVNR | AVANIR PHARMACEUTI ... | Mazzo David J | Director | Grant | A | 0.00 | 6,435 | 0 | 6,435 | 0 to 6.4 K |
| Feb 15 2006 | AVNR | AVANIR PHARMACEUTI ... | BRANDT ERIC | President, Chief Ex ... | Option Exercise | A | 15.54 | 47,800 | 742,812 | 47,800 | |
| Feb 15 2006 | AVNR | AVANIR PHARMACEUTI ... | BRANDT ERIC | President, Chief Ex ... | Option Exercise | A | 15.54 | 14,700 | 228,438 | 14,700 | |
| Dec 08 2005 | AVNR | AVANIR PHARMACEUTI ... | SIRCAR JAGADISH C | V.P. of Drug Discov ... | Option Exercise | A | 2.92 | 45,000 | 131,400 | 45,000 | |
| Dec 08 2005 | AVNR | AVANIR PHARMACEUTI ... | SIRCAR JAGADISH C | V.P. of Drug Discov ... | Option Exercise | A | 2.92 | 30,000 | 87,600 | 30,000 | |
| Dec 08 2005 | AVNR | AVANIR PHARMACEUTI ... | Katkin Keith | Sr. V.P. of Sales & ... | Option Exercise | A | 2.92 | 30,000 | 87,600 | 30,000 | |
| Dec 08 2005 | AVNR | AVANIR PHARMACEUTI ... | EMANUELE ROBERT MARTIN | V P, Business Devel ... | Option Exercise | A | 2.92 | 75,000 | 219,000 | 75,000 | |
| Dec 08 2005 | AVNR | AVANIR PHARMACEUTI ... | HANSON GREGORY P | Vice President, Fin ... | Option Exercise | A | 2.92 | 45,000 | 131,400 | 45,000 | |
| Dec 08 2005 | AVNR | AVANIR PHARMACEUTI ... | HANSON GREGORY P | Vice President, Fin ... | Option Exercise | A | 2.92 | 30,000 | 87,600 | 30,000 | |
| Oct 24 2005 | AVNR | AVANIR PHARMACEUTI ... | SILVERSTEIN JONATHAN | Director | Buy | P | 2.65 | 566,038 | 1,500,001 | 9,341,038 | 8.8 M to 9.3 M (+6.45 %) |
| Dec 08 2005 | AVNR | AVANIR PHARMACEUTI ... | BERG JAMES E | Vice President, Cli ... | Option Exercise | A | 2.92 | 100,000 | 292,000 | 100,000 | |
| Sep 22 2005 | AVNR | AVANIR PHARMACEUTI ... | EMANUELE ROBERT MARTIN | V P, Corporate Deve ... | Option Exercise | A | 3.10 | 4,000 | 12,400 | 4,000 | |
| Sep 22 2005 | AVNR | AVANIR PHARMACEUTI ... | EMANUELE ROBERT MARTIN | V P, Corporate Deve ... | Option Exercise | A | 3.10 | 31,000 | 96,100 | 31,000 | |
| Aug 16 2005 | AVNR | AVANIR PHARMACEUTI ... | BERG JAMES E | Vice President, Cli ... | Option Exercise | A | 3.10 | 8,000 | 24,800 | 8,000 | |
| Aug 16 2005 | AVNR | AVANIR PHARMACEUTI ... | BERG JAMES E | Vice President, Cli ... | Option Exercise | A | 3.10 | 27,000 | 83,700 | 27,000 | |
| Apr 12 2005 | AVNR | AVANIR PHARMACEUTI ... | SILVERSTEIN JONATHAN | Director | Buy | P | 2.20 | 900,000 | 1,980,000 | 8,775,000 | 7.9 M to 8.8 M (+11.43 %) |
| Mar 31 2005 | AVNR | AVANIR PHARMACEUTI ... | YAKATAN GERALD J PHD | President, Chief Ex ... | Grant | A | 2.65 | 2,000,000 | 5,300,000 | 2,000,000 | 0 to 2 M |
| Mar 21 2005 | AVNR | AVANIR PHARMACEUTI ... | SILVERSTEIN JONATHAN | Director | Option Exercise | A | 2.48 | 10,000 | 24,800 | 10,000 | |
| Mar 21 2005 | AVNR | AVANIR PHARMACEUTI ... | SILVERSTEIN JONATHAN | Director | Option Exercise | A | 2.48 | 25,000 | 62,000 | 25,000 | |
| Mar 21 2005 | AVNR | AVANIR PHARMACEUTI ... | OLSON KENNETH E | Director | Option Exercise | A | 2.48 | 10,000 | 24,800 | 10,000 | |
| Mar 21 2005 | AVNR | AVANIR PHARMACEUTI ... | OBERKFELL HAROLD F | Director | Option Exercise | A | 2.48 | 10,000 | 24,800 | 10,000 | |
| Mar 21 2005 | AVNR | AVANIR PHARMACEUTI ... | MATHEWS CHARLES | Director | Option Exercise | A | 2.48 | 10,000 | 24,800 | 10,000 | |
| Mar 21 2005 | AVNR | AVANIR PHARMACEUTI ... | CARLO DENNIS J PHD | Director | Option Exercise | A | 2.48 | 10,000 | 24,800 | 10,000 | |
| Mar 21 2005 | AVNR | AVANIR PHARMACEUTI ... | AUSTIN STEPHEN G | Director | Option Exercise | A | 2.48 | 10,000 | 24,800 | 10,000 | |
| Jan 03 2005 | AVNR | AVANIR PHARMACEUTI ... | HANSEN JOHN DAVID | V.P. of Corporate D ... | Sell | S | 3.40 | 10,200 | 34,680 | 15,000 | 25.2 K to 15 K (-40.48 %) |
| Jan 03 2005 | AVNR | AVANIR PHARMACEUTI ... | HANSEN JOHN DAVID | V.P. of Corporate D ... | Sell | S | 3.39 | 4,800 | 16,254 | 25,200 | 30 K to 25.2 K (-16.00 %) |
| Jan 03 2005 | AVNR | AVANIR PHARMACEUTI ... | HANSEN JOHN DAVID | V.P. of Corporate D ... | Sell | S | 3.42 | 600 | 2,052 | 15,000 | 15.6 K to 15 K (-3.85 %) |
| Jan 03 2005 | AVNR | AVANIR PHARMACEUTI ... | HANSEN JOHN DAVID | V.P. of Corporate D ... | Sell | S | 3.41 | 14,400 | 49,044 | 15,600 | 30 K to 15.6 K (-48.00 %) |
| Nov 12 2004 | AVNR | AVANIR PHARMACEUTI ... | YAKATAN GERALD J PHD | President, Chief Ex ... | Option Exercise | A | 3.46 | 135,000 | 467,100 | 144,248 | |
| Nov 12 2004 | AVNR | AVANIR PHARMACEUTI ... | YAKATAN GERALD J PHD | President, Chief Ex ... | Option Exercise | A | 3.46 | 9,248 | 31,998 | 9,248 | |
| Nov 12 2004 | AVNR | AVANIR PHARMACEUTI ... | YAKATAN GERALD J PHD | President, Chief Ex ... | Option Exercise | A | 3.46 | 55,752 | 192,902 | 55,752 | |
| Nov 12 2004 | AVNR | AVANIR PHARMACEUTI ... | SMITH VICTORIA | V.P. of Administati ... | Option Exercise | A | 3.46 | 35,000 | 121,100 | 35,000 | |
| Nov 12 2004 | AVNR | AVANIR PHARMACEUTI ... | SIRCAR JAGADISH C | V.P. of Drug Discov ... | Option Exercise | A | 3.46 | 10,988 | 38,018 | 10,988 | |
| Nov 12 2004 | AVNR | AVANIR PHARMACEUTI ... | SIRCAR JAGADISH C | V.P. of Drug Discov ... | Option Exercise | A | 3.46 | 39,012 | 134,982 | 39,012 | |
| Nov 12 2004 | AVNR | AVANIR PHARMACEUTI ... | HANSON GREGORY P | Vice President, Fin ... | Option Exercise | A | 3.46 | 50,000 | 173,000 | 50,000 | |
| Nov 12 2004 | AVNR | AVANIR PHARMACEUTI ... | HANSON GREGORY P | Vice President, Fin ... | Option Exercise | A | 3.46 | 50,000 | 173,000 | 50,000 | |
| Nov 12 2004 | AVNR | AVANIR PHARMACEUTI ... | HANSEN JOHN DAVID | V.P. of Corporate D ... | Option Exercise | A | 3.46 | 50,000 | 173,000 | 50,000 | |
| Nov 12 2004 | AVNR | AVANIR PHARMACEUTI ... | FERNANDEZ GUS | V.P. of Commercial ... | Option Exercise | A | 3.46 | 24,831 | 85,915 | 24,831 | |
| Nov 12 2004 | AVNR | AVANIR PHARMACEUTI ... | FERNANDEZ GUS | V.P. of Commercial ... | Option Exercise | A | 3.46 | 50,169 | 173,585 | 50,169 | |
| Nov 12 2004 | AVNR | AVANIR PHARMACEUTI ... | EMANUELE ROBERT MARTIN | V P, Corporate Deve ... | Option Exercise | A | 3.46 | 50,000 | 173,000 | 50,000 | |
| Nov 12 2004 | AVNR | AVANIR PHARMACEUTI ... | EMANUELE ROBERT MARTIN | V P, Corporate Deve ... | Option Exercise | A | 3.46 | 50,000 | 173,000 | 50,000 | |
| Nov 12 2004 | AVNR | AVANIR PHARMACEUTI ... | BERG JAMES E | Vice President, Cli ... | Option Exercise | A | 3.46 | 32,427 | 112,197 | 32,427 | |
| Nov 12 2004 | AVNR | AVANIR PHARMACEUTI ... | BERG JAMES E | Vice President, Cli ... | Option Exercise | A | 3.46 | 42,573 | 147,303 | 42,573 | |
| Sep 14 2004 | AVNR | AVANIR PHARMACEUTI ... | HANSEN JOHN DAVID | V.P. of Corporate D ... | Sell | S | 3.15 | 15,000 | 47,259 | 30,000 | 45 K to 30 K (-33.33 %) |
| Sep 14 2004 | AVNR | AVANIR PHARMACEUTI ... | HANSEN JOHN DAVID | V.P. of Corporate D ... | Sell | S | 3.15 | 15,000 | 47,259 | 30,000 | 45 K to 30 K (-33.33 %) |
| Jun 14 2004 | AVNR | AVANIR PHARMACEUTI ... | BERG JAMES E | Vice President, Cli ... | Option Exercise | X | 0.30 | 8,000 | 2,400 | 0 | |
| Jun 14 2004 | AVNR | AVANIR PHARMACEUTI ... | BERG JAMES E | Vice President, Cli ... | Buy | X | 0.30 | 8,000 | 2,400 | 49,000 | 41 K to 49 K (+19.51 %) |
| Apr 08 2004 | AVNR | AVANIR PHARMACEUTI ... | SMITH VICTORIA | V.P. of Administati ... | Option Exercise | A | 1.78 | 10,000 | 17,800 | 10,000 |